PL EN


Preferences help
enabled [disable] Abstract
Number of results
2014 | 68 | 4 | 192–199
Article title

Polimorfizm 575C/T genu RANK i jego związek z osteoporozą u kobiet po menopauzie

Content
Title variants
EN
575C/T polymorphism of RANK gene and its association with osteoporosis in postmenopausal women
Languages of publication
PL
Abstracts
EN
INTRODUCTION Osteoporosis is a skeletal disturbance in which bone strength is at increased risk of fracture. It was demonstrated that genetic variations in RANK are associated with skeletal diseases. AIM OF STUDY The aim of the study is to examine the frequency of RANK gene polymorphism and evaluate its relation with clinical parameters concerning bone turnover and the degree of postmenopausal osteoporosis progress. MATERIAL AND METHODS The study was conducted among a group of 570 women at postmenopausal age (404) and reproductive age (166). The group at postmenopausal age included women with osteoporosis, osteopenia and healthy individuals. The women at reproductive age were healthy. The polymorphism incidence of the examined gene in a group of patients with a determined bone mineral density (BMD) and in the control group was studied. The study was performed by means of the RFLP-PCR method. RESULTS The obtained results did not show a correlation of RANK C575T polymorphism with decreased bone density or increased risk of postemopausal osteoporosis incidence. CONCLUSIONS The TT polymorphism homozygote of the RANK receptor gene is not an increased risk factor of osteoporosis development and is associated with lower values describing bone density in women with osteoporosis and osteopenia.
PL
W S T Ę P Osteoporoza jest szkieletowym zaburzeniem charakteryzującym się obniżeniem wytrzymałości kości, zwiększającym ryzyko złamania. Wykazano, że genetyczne wariacje w RANK mają związek z chorobami szkieletu kostnego. Celem pracy było zbadanie częstości występowania polimorfizmu genu RANK oraz ocena jego związku z parametrami klinicznymi dotyczącymi obrotu kostnego i stopnia zaawansowania osteoporozy pomenopauzalnej. M A T E R I A Ł Y I M E T O D Y Badania przeprowadzono w grupie 570 kobiet w wieku postmenopauzalnym (404) i rozrodczym (166). Grupa w wieku postmenopauzalnym obejmowała kobiety z osteoporozą, osteopenią i zdrowe. Kobiety w wieku rozrodczym były zdrowe. Zbadano częstość występowania polimorfizmu badanego genu w grupie pacjentek z oznaczoną gęstością mineralną kości (bone mineral density – BMD) oraz w grupie kontrolnej. Badanie przeprowadzono metodą RFLP-PCR. WYNIKI Uzyskane wyniki badań nie wykazały korelacji polimorfizmu RANK C575T ze zmniejszoną gęstością kości oraz zwiększonym ryzykiem występowania osteoporozy pomenopauzalnej. WNIOSKI Homozygota TT polimorfizmu genu receptora RANK nie jest czynnikiem zwiększonego ryzyka wystąpienia osteoporozy i jest powiązana z niższymi wartościami opisującymi BMD u kobiet z osteoporozą i osteopenią.
Keywords
Discipline
Publisher

Year
Volume
68
Issue
4
Pages
192–199
Physical description
Contributors
  • Katedra i Zakład Histologii Wydziału Lekarskiego z Oddziałem Lekarsko-Dentystycznym w Zabrzu Śląskiego Uniwersytetu Medycznego w Katowicach ul. Jordana 19 41-808 Zabrze tel. +48 32 272 28 42, e-mail: dariusz@boron.pl
author
  • Centrum Dydaktyki i Symulacji Medycznej Śląskiego Uniwersytetu Medycznego w Katowicach
  • Zakład Komputerowych Systemów Biomedycznych Uniwersytetu Śląskiego w Katowicach
References
  • 1. Tilg H., Moschen A.R., Kaser A., Pines A., Dotan I. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 2008; 57: 684–694.
  • 2. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003; 423: 337–342.
  • 3. Blair J.M., Zheng Y., Dunstan C.R. Molecules in focus. RANK ligand. Int. J. Biochem. Cell Biol. 2007; 39: 1077–1081.
  • 4. Schoppet M., Preissner K.T., Hofbauer L.C. RANK ligand and osteoprotegerin: paracrie regulators of bone metabolism and vascular function. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 549–553.
  • 5. Theill L.E., Boyle W.J., Penninger J.M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 2002; 20: 795–823.
  • 6. Trouvin A.P., Goeb V. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin. Interv. Aging. 2010; 5: 345–354.
  • 7. Jones D.H., Kong Y.Y., Penninger J.M. Role of RANKL and RANK in bone loss and arthritis. Ann. Rheum. Dis. 2002; 61(Suppl 2): 32–39.
  • 8. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ. Res. 2004; 95: 1046–1057.
  • 9. Suda T., Kobayashi K., Jimi E., Udagawa N., Takahashi N. The molecular basis of osteoclast differentiation and activation. Novartis Found. Symp. 2001; 232: 235–247.
  • 10. Sordillo E.M., Pearse R.N. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer 2003; 97(3 Suppl): 802–812.
  • 11. Chan K.F., Siegel M.R., Lenardo J.M. Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 2000; 13: 419–422.
  • 12. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487–501.
  • 13. Williamson E., Bilsborough J.M., Viney J.L. Regulation of mucosal dendritic cell function by receptor activator of NF-B (RANK)/RANK ligand interactions: impact on tolerance induction. J. Immunol. 2002; 169: 3606–3612.
  • 14. Yu Q., Gu J.X., Kovacs C., Freedman J., Thomas E.K., Ostrowski M.A. Cooperation of TNF family members CD40 ligand, receptor activator of NF-B ligand, and TNF- in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. J. Immunol. 2003; 170: 1797–1805.
  • 15. Gonzalez-Suarez E., Branstetter D., Armstrong A., Dinh H., Blumberg H., Dougall W.C. RANK over expression in transgenic mice with mouse mammary tumor virus promoter controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. Mol. Cell Biol. 2007; 27: 1442–1454.
  • 16. Abrams S.A. Normal acquisition and loss of bone mass. Horm. Res. 2003; 60 Suppl 3: 71–76.
  • 17. Heaney R.P., Abrams S., Dawson-Hughes B. i wsp. Peak bone mass. Osteoporos. Int. 2000; 11: 985–1009.
  • 18. Leibbrandt A., Penninger J.M. RANK/RANKL: regulators of immune responses and bone physiology. Ann. NY Acad. Sci. 2008; 1143: 123–150.
  • 19. Wada T., Nakashima T., Hiroshi N., Penninger J.M. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med. 2006; 12: 17–25.
  • 20. Choi J.Y., Shin A., Park S.K. i wsp. Genetic polymorphisms of OPG, RANK, and ESR1 and bone mineral density in Korean postmenopausal women. Calcif Tissue Int. 2005; 77: 152–159.
  • 21. Hsu Y.H., Niu T., Terwedow H.A. i wsp. Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. Hum. Genet. 2006; 118: 568–577.
  • 22. Kim J.G., Kim J.H., Kim J.Y. i wsp. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-B (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause 2007; 14: 913–918.
  • 23. Koh J.M., Park B.L., Kim D.J. i wsp. Identification of novel RANK polymorphisms and their putative association with low BMD among postmenopausal women. Osteoporos. Int. 2007; 18: 323–331.
  • 24. Liu J.M., Zhang M.J., Zhao L. i wsp. Analysis of recently identified osteoporosis susceptibility genes in Han Chinese Women. J. Clin. Endocrinol. Metab. 2010; 95: 112–120.
  • 25. Lu Y., Liu P., Recker R.R., Deng H.W., Dvornyk V. TNFRSF11A and TNFSF11 are associated with age at menarche and natural menopause in white women. Menopause 2010; 17: 1048–1054.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-dfdb1084-640c-4eef-9088-4cd6b561abca
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.